Cyteir Therapeutics, Inc. (CYT) Research

Cyteir Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to innovating and bringing to market cutting-edge precision oncology medicines. Its flagship compound, CYT-0851, is an novel, orally administered small molecule drug candidate, designed for once-daily dosing. This therapy is currently undergoing Phase I/II clinical evaluations, both as a standalone treatment and in combination with other drugs, targeting a broad range of solid tumors and hematologic malignancies. Furthermore, the company is advancing CYT-1853, another promising candidate in preclinical development for similar oncological indications. Cyteir Therapeutics was established in 2012 and is headquartered in Lexington, Massachusetts.

Market snapshot

Symbol
CYT
Price
$3.02
Day change
-2.27%
Market cap
$108.7M
P/E ratio
-2.42x
52-week range
1.65-3.19
Sector
Healthcare
Industry
Biotechnology
Analyst price target
$2.00

Peer companies

  • Aadi Bioscience, Inc. (AADI)
  • Decibel Therapeutics, Inc. (DBTX)
  • Graybug Vision, Inc. (GRAY)
  • HilleVax, Inc. (HLVX)
  • Jounce Therapeutics, Inc. (JNCE)
  • Kinnate Biopharma Inc. (KNTE)
  • Miromatrix Medical Inc. (MIRO)
  • Opiant Pharmaceuticals, Inc. (OPNT)

Recent insider activity

  • Leonard Braden Michael — P-Purchase (170589 shares) on 2024-03-20
  • Leonard Braden Michael — P-Purchase (113777 shares) on 2024-03-18
  • Leonard Braden Michael — trade (0 shares) on 2024-03-15
  • Leonard Braden Michael — trade (0 shares) on 2024-03-15
  • Gaiero David G — M-Exempt (2373 shares) on 2024-03-04

Open Cyteir Therapeutics, Inc. (CYT) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.